0000313143-23-000037.txt : 20230807 0000313143-23-000037.hdr.sgml : 20230807 20230807161909 ACCESSION NUMBER: 0000313143-23-000037 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20230804 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Submission of Matters to a Vote of Security Holders ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230807 DATE AS OF CHANGE: 20230807 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HAEMONETICS CORP CENTRAL INDEX KEY: 0000313143 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 042882273 STATE OF INCORPORATION: MA FISCAL YEAR END: 0330 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-14041 FILM NUMBER: 231147879 BUSINESS ADDRESS: STREET 1: 125 SUMMER STREET CITY: BOSTON STATE: MA ZIP: 02110 BUSINESS PHONE: 7818487100 MAIL ADDRESS: STREET 1: 125 SUMMER STREET CITY: BOSTON STATE: MA ZIP: 02110 8-K 1 hae-20230804.htm 8-K hae-20230804
0000313143false00003131432023-08-042023-08-04

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 4, 2023

HAEMONETICS CORPORATION
(Exact name of registrant as specified in its charter)
Massachusetts001-1404104-2882273
(State or other jurisdiction
of incorporation)
(Commission File Number)
(I.R.S. Employer
Identification No.)

125 Summer Street
Boston, MA 02110
(Address of principal executive offices, including zip code)
Registrant’s telephone number, including area code: 781-848-7100
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common stock, $.01 par value per shareHAENew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging Growth Company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.








Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(d)

On August 4, 2023, the Board of Directors of Haemonetics Corporation (the “Company”) elected Diane M. Bryant as a director of the Company, effective immediately. Ms. Bryant recently served as Chairman and Chief Executive Officer of NovaSignal Corp., a medical technology and data company specializing in the assessment and management of brain health. Ms. Bryant previously served as Chief Operating Officer at Google Cloud and, prior to joining Google Cloud, spent 32 years at Intel Corporation where she held numerous leadership positions of increasing responsibility, including serving as Group President of the Data Center Group.

Ms. Bryant, who will stand for election by shareholders at the Company’s 2024 annual meeting of shareholders, has also been appointed to serve on the Compensation Committee and Technology Committee of the Board of Directors. As a non-employee director of the Company, Ms. Bryant will receive compensation as described in the “Directors’ Compensation” section of the Company’s definitive proxy statement for the 2023 annual meeting of shareholders, with an annual equity award having an approximate value of $200,000. Ms. Bryant will also enter into the Company's standard form of indemnification agreement, the form of which was previously filed as Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q for the quarterly period ended September 29, 2018.

A copy of the Company’s press release announcing the election of Ms. Bryant is filed as Exhibit 99.1 to this Current Report on Form 8-K.

(e)

As described in Item 5.07 below, on August 4, 2023, the shareholders of the Company approved an amendment and restatement of the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan (the “Amended Plan”), which authorizes 2,966,231 new shares for issuance under the Amended Plan and makes certain other changes, including clarifying certain definitions, adding objectively determinable corporate values measures to the types of performance goals that may be applicable to an award, clarifying certain exercisability provisions relating to stock options, augmenting language relating to compensation recoupment provisions and extending the term of the Amended Plan until August 3, 2033. A description of the material terms and conditions of the Amended Plan is provided in Item 4 of the Company’s definitive proxy statement for the 2023 annual meeting of shareholders, which was filed with the Securities and Exchange Commission on June 16, 2023 and is incorporated herein by reference.

The foregoing description of the Amended Plan is qualified in its entirety by reference to a full and complete copy of the Amended Plan, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 5.07 Submission of Matters to a Vote of Security Holders.

The Company’s 2023 Annual Meeting of Shareholders was held on Friday, August 4, 2023. Of the 50,594,781 shares outstanding and entitled to vote at the meeting, 48,447,497 shares were represented at the meeting, constituting a quorum of 95.75%.

The results of the votes for each proposal considered at the meeting are set forth below:

1. The shareholders elected each of Christopher A. Simon, Robert E. Abernathy, Michael J. Coyle, Charles J. Dockendorff, Lloyd E. Johnson, Mark W. Kroll, Claire Pomeroy and Ellen M. Zane as directors for one-year terms expiring in 2024 based upon the following votes:




NomineesForWithholdBroker Non-Votes
Christopher A. Simon46,433,691328,7141,685,092
Robert E. Abernathy45,088,2421,674,1631,685,092
Michael J. Coyle46,424,781337,6241,685,092
Charles J. Dockendorff45,030,1971,732,2081,685,092
Lloyd E. Johnson42,123,2094,639,1961,685,092
Mark W. Kroll46,097,712664,6931,685,092
Claire Pomeroy46,378,877383,5281,685,092
Ellen M. Zane39,666,5737,095,8321,685,092

2. The shareholders approved, on an advisory basis, the compensation of the Company’s named executive officers based upon the following votes:

ForAgainstAbstainBroker Non-Votes
44,958,5771,776,92826,9001,685,092

3. The shareholders approved, on an advisory basis, a frequency of one year for future advisory votes on the compensation of the Company’s named executive officers. The Board considered these voting results and other factors, and determined that the Company will hold future advisory votes on its executive compensation on an annual basis.

One YearTwo YearsThree YearsAbstainBroker Non-Votes
45,575,266175,185987,40424,5501,685,092

4. The shareholders approved a proposal to adopt an amendment and restatement of the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan based upon the following votes:

ForAgainstAbstainBroker Non-Votes
45,678,5061,058,80825,0911,685,092

5. The shareholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending March 30, 2024 based upon the following votes:

ForAgainstAbstain
47,679,417748,04920,031

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit NumberDescription
Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan
Press release dated August 7, 2023
104Cover Page Interactive Data File (embedded within the Inline XBRL document)




SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
HAEMONETICS CORPORATION
August 7, 2023By:/s/ Christopher A. Simon
Name:Christopher A. Simon
Title:President and Chief Executive Officer


EX-10.1 2 a8kex101-ar2019ltiplan8723.htm EX-10.1 Document

Exhibit 10.1

HAEMONETICS CORPORATION
AMENDED AND RESTATED 2019 LONG-TERM INCENTIVE COMPENSATION PLAN
Effective as of the Effective Date (as defined below), the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan is hereby amended and restated (as amended and restated, the “Plan”).
The purpose of the Plan is to provide employees of Haemonetics Corporation (the “Company”) and its subsidiaries, certain consultants and advisors who perform services for the Company and its subsidiaries, and non-employee members of the Board of Directors of the Company and its subsidiaries, with the opportunity to receive grants of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock, restricted stock units, other stock-based awards, and/or cash awards.
The Company believes that the Plan will encourage the participants to contribute to the success and/or growth of the Company, thereby benefiting the Company’s stockholders, and will align the economic interests of the participants with those of the stockholders.
The Plan is a successor to the Haemonetics Corporation 2005 Long-Term Incentive Compensation Plan (the “Prior Plan”). Effective July 25, 2019, no additional grants may be made under the Prior Plan, provided that outstanding grants under the Prior Plan shall continue in effect according to their terms, consistent with the Prior Plan.
Section 1.    Definitions
Capitalized terms used in the Plan and not defined elsewhere in the Plan shall have the meaning set forth in this Section below:
(a)    “Award” shall mean an Option, SAR, Restricted Stock, Restricted Stock Unit, Other Stock-Based Award, or Cash Award granted under the Plan.
(b)    “Award Agreement” shall mean the written agreement that sets forth the terms and conditions of an Award, including all amendments thereto.
(c)    “Board” shall mean the Board of Directors of the Company.
(d)    “Cash Award” shall mean a cash incentive payment awarded under this Plan as described under Section 11.
(e)    “Cause” shall have the meaning given to that term in any written employment agreement, change-of-control agreement, offer letter or severance agreement between the Employer and the Participant, or if no such agreement exists or if such term is not defined therein, and unless otherwise defined in the Award Agreement, Cause shall mean that the Participant:




(i)    has materially breached his or her employment or service contract with the Employer, which breach has not been remedied by the Participant after written notice has been provided to the Participant of such breach;
(ii)    has engaged in disloyalty to the Employer, including without limitation, fraud, embezzlement, theft, commission of a felony or proven dishonesty, any of which results in economic loss, damage, or injury to the Employer;
(iii)    has disclosed trade secrets or confidential information of the Employer to persons not entitled to receive such information;
(iv)    has breached any written noncompetition, nonsolicitation or other restrictive covenant agreement between the Participant and the Employer; or
(v)    has engaged in gross misconduct or a willful and material violation of the Company’s policies and procedures that is injurious to the Company.
For the avoidance of doubt, the occurrence of any of the actions set forth in clauses (i) through (v) immediately above shall be determined by the Committee in good faith.
(f)    “CEO” shall mean the Chief Executive Officer of the Company.
(g)    Unless otherwise set forth in an Award Agreement, a “Change of Control” shall be deemed to have occurred if:
(i)    a person, or any two or more persons acting as a group, and all affiliates of such person or persons, who prior to such time owned less than fifty percent (50%) of the Company’s then outstanding shares of Company Stock, shall acquire such additional shares of Company Stock in one or more transactions, or series of transactions, such that following such transaction or transactions such person or group and affiliates beneficially own fifty percent (50%) or more of the Company Stock outstanding;
(ii)    closing of the sale of all or substantially all of the assets of the Company on a consolidated basis to an unrelated person or entity;
(iii)    individuals who constitute the Incumbent Board cease for any reason to constitute at least a majority of the Company’s Board (for this purpose, “Incumbent Board” means at any time those persons who are then members of the Company’s Board of Directors and who are either (y) members of the Company’s Board of Directors on the Effective Date, or (z) have been elected, or have been nominated for election by the Company’s stockholders, by the affirmative vote of at least two-thirds of the directors comprising the Incumbent Board at the time of such election or nomination (either by a specific vote or by approval of the proxy statement of the Company in which such person is named as a nominee for director without objection to such nomination); or
(iv)    the consummation of any merger, reorganization, consolidation or share exchange unless the persons who were the beneficial owners of the Company’s outstanding shares of Company Stock immediately before the consummation of such transaction beneficially

- 2 -


own more than 50% of the outstanding shares of the common stock of the successor or survivor entity in such transaction immediately following the consummation of such transaction. For purposes of this definition, the percentage of the beneficially owned shares of the successor or survivor entity described above shall be determined exclusively by reference to the shares of the successor or survivor entity which result from the beneficial ownership of Company Stock by the persons described above immediately before the consummation of such transaction.
(h)    “Code” shall mean the Internal Revenue Code of 1986, as amended, and the regulations promulgated thereunder.    
(i)    “Committee” shall mean the Compensation Committee of the Board or another committee appointed by the Board to administer the Plan. The Committee shall also consist of directors who are “non-employee directors” as defined under Rule 16b-3 promulgated under the Exchange Act and “independent directors,” as determined in accordance with the independence standards established by the stock exchange on which the Company Stock is at the time primarily traded.
(j)    “Company” shall mean Haemonetics Corporation, a company organized under the laws of the Commonwealth of Massachusetts.
(k)    “Company Stock” shall mean common stock of the Company.
(l)    “Disability” or “Disabled” shall mean, unless otherwise defined in an employment agreement between the Participant and the Company, a condition whereby the Participant (i) is unable to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment which can be expected to result in death or can be expected to last for a continuous period of not less than 12 months; or (ii) is determined to be totally disabled by the Social Security Administration, provided that each qualifies as a disability within the meaning of Code Section 409A.
(m)    “Dividend Equivalent” shall mean an amount determined by multiplying the number of shares of Company Stock subject to a Restricted Stock Unit or Other Stock-Based Award by the per-share cash dividend paid by the Company on its outstanding Company Stock, or the per-share Fair Market Value of any dividend paid on its outstanding Company Stock in consideration other than cash. If interest is credited on accumulated divided equivalents, the term “Dividend Equivalent” shall include the accrued interest.
(n)    “Effective Date” shall mean the date on which the Plan is approved by the Company’s stockholders.
(o)    “Employee” shall mean an employee of the Employer (including an officer or director who is also an employee) but excluding any person who is classified by the Employer as a “contractor” or “consultant,” no matter how characterized by the Internal Revenue Service, other governmental agency or a court. Any change of characterization of an individual by the Internal Revenue Service or any court or government agency shall have no effect upon the classification of an individual as an Employee for purposes of this Plan unless the Committee determines otherwise.

- 3 -


(p)    “Employed by, or providing service to, the Employer” shall mean employment or service as an Employee, Key Advisor, member of the Board or a member of a board of directors of a subsidiary of the Company (so that, for purposes of exercising Options and SARs and satisfying conditions with respect to Restricted Stock, Restricted Stock Units, Other Stock-Based Awards, and Cash Awards, a Participant shall not be considered to have terminated employment or service until the Participant ceases to be an Employee, Key Advisor, member of the Board, or member of the board of a subsidiary of the Company), unless the Committee determines otherwise. If a Participant’s relationship is with a subsidiary of the Company and that entity ceases to be a subsidiary of the Company, the Participant will be deemed to cease employment or service when the entity ceases to be a subsidiary of the Company, unless the Participant transfers employment or service to an Employer.
(q)    “Employer” shall mean the Company and its subsidiaries.
(r)    “Exchange Act” shall mean the Securities Exchange Act of 1934, as amended.
(s)    “Exercise Price” shall mean the per share price at which shares of Company Stock may be purchased under an Option, as designated by the Committee.
(t)    “Fair Market Value” shall mean:
(i)    If the Company Stock is publicly traded, the Fair Market Value per share shall be determined as follows: (A) if the principal trading market for the Company Stock is a national securities exchange, the closing sales price per share of Company Stock, as reported by such exchange, during regular trading hours on the relevant date or, if there were no trades on that date, the latest preceding date upon which a sale was reported, or (B) if the Company Stock is not principally traded on any such exchange, the last reported sale price of a share of Company Stock during regular trading hours on the relevant date, as reported by the OTC Bulletin Board.
(ii)    If the Company Stock is not publicly traded or, if publicly traded, is not subject to reported transactions as set forth above, the Fair Market Value per share shall be determined by the Committee through any reasonable valuation method and, if required, that is authorized under the Code.
(u)    “Incentive Stock Option” shall mean an Option that is intended to meet the requirements of an incentive stock option under section 422 of the Code.
(v)    “Key Advisor” shall mean a consultant or advisor of the Employer.
(w)    “Non-Employee Director” shall mean a member of the Board who is not an Employee.
(x)    “Nonqualified Stock Option” shall mean an Option that is not intended to be taxed as an incentive stock option under section 422 of the Code.
(y)    “Option” shall mean an option to purchase shares of Company Stock, as described in Section 6.

- 4 -



(z)    “Other Stock-Based Award” shall mean any Award based on, measured by or payable in Company Stock (other than an Option, Restricted Stock Unit, Restricted Stock, or SAR), as described in Section 10.
(aa)    “Participant” shall mean an Employee, Key Advisor or Non-Employee Director designated by the Committee to participate in the Plan.
(bb)    “Performance Goals” shall mean performance goals based on, but are not limited to, one or more of the following criteria: revenue; earnings per share; operating income; net income (before or after taxes); cash flow (including, but not limited to, operating cash flow and free cash flow); gross profit; growth in any of the preceding measures; gross profit return on investment; gross margin return on investment; working capital; gross margins; EBIT; EBITDA; return on equity; return on assets; return on capital; revenue growth; total shareholder return; economic value added; customer satisfaction; technology leadership; number of new patents; employee retention; market share; market segment share; product release schedules; new product innovation; cost reduction through advanced technology; brand recognition/acceptance; product ship targets; corporate values measures that may be objectively determined, including, without limitation, with respect to product quality, human capital management and environment, health and safety; and stock value; and other similar criteria consistent with the foregoing. Performance goals applicable to an Award shall be determined by the Committee, and may be measured in terms of any period, including calendar year, fiscal year, or any longer or shorter period as determined by the Committee. Performance goals may be established on an absolute or relative basis, on a GAAP or non-GAAP basis, and may be established on a corporate-wide basis, or on objectives that are related to the performance of an individual Participant, or with respect to one or more business units, departments, divisions, subsidiaries or business segments. Relative performance may be measured against a group of peer companies, a financial market index or other objective and quantifiable indices.
(cc)    “Plan” shall mean this Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan, as amended and restated hereby.
(dd)    “Restricted Stock” shall mean an award of Company Stock, as described in Section 7.
(ee)    “Restricted Stock Unit” shall mean an award of a phantom unit representing a share of Company Stock, as described in Section 8.
(ff)    “Restriction Period” shall have the meaning given that term in Section 7(a).
(gg)    “SAR” shall mean a stock appreciation right, as described in Section 9.
(hh)    “Substitute Awards” shall have the meaning given that term in Section 4(c).



- 5 -


Section 2.    Administration
(a)    Committee. The Plan shall be administered and interpreted by the Committee. The Committee may delegate authority to one or more subcommittees, as it deems appropriate. Subject to compliance with applicable law and the applicable stock exchange rules, the Board, in its discretion, may perform any action of the Committee hereunder. To the extent that the Board, the Committee, a subcommittee or the CEO, as described below administers the Plan, references in the Plan to the “Committee” shall be deemed to refer to the Board, the Committee or such subcommittee or the CEO.
(b)    Delegation to CEO. Subject to compliance with applicable law and applicable stock exchange requirements, the Committee may delegate all or part of its authority and power to the CEO, as it deems appropriate, with respect to Awards to Employees or Key Advisors who are not officers or directors under section 16 of the Exchange Act.
(c)    Committee Authority. The Committee shall have the sole authority to (i) determine the individuals to whom Awards shall be made under the Plan, (ii) determine the type, size, terms and conditions of the Awards to be made to each such individual, (iii) determine the time when the Awards will be made and the duration of any applicable exercise or restriction period, including the criteria for exercisability and the acceleration of exercisability, (iv) amend the terms of any previously issued Award, subject to the provisions of Section 18 below, (v) determine and adopt terms, guidelines, and provisions, not inconsistent with the Plan and applicable law, that apply to individuals residing outside the United States who receive Awards under the Plan, and (vi) deal with any other matters arising under the Plan.
(d)    Committee Determinations. The Committee shall have full power and express discretionary authority to administer and interpret the Plan, to make factual determinations and to adopt or amend such rules, regulations, agreements and instruments for implementing the Plan and for the conduct of its business as it deems necessary or advisable, in its sole discretion. The Committee’s interpretations of the Plan and all determinations made by the Committee pursuant to the powers vested in it hereunder shall be final, conclusive and binding on all persons having any interest in the Plan or in any awards granted hereunder. All powers of the Committee shall be executed in its sole discretion, in the best interest of the Company, not as a fiduciary, and in keeping with the objectives of the Plan and need not be uniform as to similarly situated individuals.
Section 3.    Awards
(a)    General. Awards under the Plan may consist of Options as described in Section 6, Restricted Stock as described in Section 7, Restricted Stock Units as described in Section 8, SARs as described in Section 9, Other Stock-Based Awards as described in Section 10, and Cash Awards as described in Section 11. All Awards shall be subject to the terms and conditions set forth herein and to such other terms and conditions consistent with this Plan as the Committee deems appropriate and as are specified in writing by the Committee to the individual in the Award Agreement. All Awards shall be made conditional upon the Participant’s acknowledgement, in writing or by acceptance of the Award, that all decisions and determinations of the Committee shall be final and binding on the Participant, his or her

- 6 -


beneficiaries and any other person having or claiming an interest under such Award. Awards under a particular Section of the Plan need not be uniform as among the Participants.
Section 4.    Shares Subject to the Plan
(a)    Shares Authorized. Subject to adjustment as described below in Sections 4(b) and 4(e) below, the aggregate number of shares of Company Stock, or share reserve, that may be issued or transferred under the Plan shall be 4,942,201 shares (including, for the avoidance of doubt, shares of Company Stock issued under the Plan prior to the amendment and restatement of the Plan). In addition, and subject to adjustment as provided in Sections 4(b) and 4(e) below, shares of Company Stock subject to outstanding grants under the Prior Plan that terminate, expire or are cancelled, forfeited, exchanged or surrendered on or after July 25, 2019 without having been exercised, vested or paid under the Prior Plan shall be added to the share reserve under the Plan (the “Prior Plan Returned Shares”). The aggregate number of shares of Company Stock that may be issued or transferred under the Plan pursuant to Incentive Stock Options shall not exceed 4,942,201 shares of Company Stock.
(b)    Source of Shares; Share Counting. Shares issued or transferred under the Plan may be authorized but unissued shares of Company Stock or reacquired shares of Company Stock, including shares purchased by the Company on the open market for purposes of the Plan. Any shares that are subject to an Award of Options or SARs shall be counted against the share reserve authorized in Section 4(a) as one (1) share; and any shares that are subject to Awards other than Options, SARs, or Cash Awards, shall be counted against the share reserve authorized in Section 4(a) as 2.76 shares (the “Fungible Ratio”). Any shares that become available for reissuance pursuant to the terms of the Plan, including any Prior Plan Returned Shares, will be returned to the share reserve at the rates described in the preceding sentences of this Section 4(b). If and to the extent Options or SARs granted under the Plan or options, restricted stock, restricted stock units, or other stock based awards granted under the Prior Plan terminate, expire or are canceled, forfeited, exchanged or surrendered without having been exercised, or if any Restricted Stock, Restricted Stock Units or Other Stock-Based Awards are forfeited or terminated, the shares subject to such Awards shall again be available for purposes of the Plan. Shares surrendered or withheld in payment of the Exercise Price of an Option (including an option granted under the Prior Plan that is exercised on or after the Effective Date) or SAR shall not be available for reissuance under the Plan. Shares of Company Stock withheld or surrendered for payment of taxes with respect to Awards (including options granted under the Prior Plan) shall not be available for reissuance under the Plan. If SARs are granted, the full number of shares subject to the SARs shall be considered issued under the Plan, without regard to the number of shares issued upon exercise of the SARs. To the extent any Awards are paid in cash, and not in shares of Company Stock, any shares previously subject to such Awards shall again be available for issuance or transfer under the Plan. For the avoidance of doubt, if shares are repurchased by the Company on the open market with the proceeds of the Exercise Price of Options (including options granted under the Plan prior to the Effective Date), such shares may not again be made available for issuance under the Plan.
(c)    Substitute Awards. Shares issued or transferred under Awards made pursuant to an assumption, substitution or exchange for previously granted awards of a company acquired by the Company in a transaction (“Substitute Awards”) shall not reduce the number of

- 7 -


shares of Company Stock available under the Plan, and available shares under a stockholder approved plan of an acquired company (as appropriately adjusted to reflect the transaction) may be used for Awards under the Plan and shall not reduce the Plan’s share reserve (subject to applicable stock exchange listing and Code requirements).
(d)    Individual Limits. Subject to adjustment as described below in Section 4(e), the following Award limitations shall apply:
(i)    For Options, SARs, Restricted Stock, Restricted Stock Units and Other Stock-Based Awards (whether payable in Company Stock, cash or a combination of the two), the maximum number of shares of Company Stock for which such Awards may be made to any Employee or Key Advisor in any fiscal year shall not exceed 750,000 shares of Company Stock in the aggregate, without regard to, and prior to any application of, the Fungible Ratio.
(ii)    The maximum aggregate grant date value of shares of Company Stock subject to Awards granted to any Non-Employee Director during any calendar year for services rendered as a Non-Employee Director, taken together with any cash fees earned by such Non-Employee Director for services rendered as a Non-Employee Director during the fiscal year, shall not exceed $750,000 in total value. For purposes of this limit, the value of such Awards shall be calculated based on the grant date fair value of such Awards for financial reporting purposes.
(iii)    Notwithstanding the foregoing, the individual limit described in subsection (i) shall be increased to two times the otherwise applicable limit with respect to Awards that are made on or around the date of hire to a newly hired Employee.
(e)    Adjustments. If there is any change in the number or kind of shares of Company Stock outstanding by reason of (i) a stock dividend, spinoff, recapitalization, stock split, reverse stock split, or combination or exchange of shares, (ii) a merger, reorganization or consolidation, (iii) a reclassification or change in par value, or (iv) any other extraordinary or unusual event affecting the outstanding Company Stock as a class without the Company’s receipt of consideration, or if the value of outstanding shares of Company Stock is substantially reduced as a result of a spinoff or the Company’s payment of an extraordinary dividend or distribution, the maximum number and kind of shares of Company Stock available for issuance under the Plan, the maximum number and kind of shares of Company Stock for which any individual may receive Awards in any year, the number and kind of shares covered by outstanding Awards, the number and kind of shares issued and to be issued under the Plan, and the price per share or the applicable market value of such Awards shall be equitably adjusted by the Committee to reflect any increase or decrease in the number of, or change in the kind or value of, the issued shares of Company Stock to preclude, to the extent practicable, the enlargement or dilution of rights and benefits under the Plan and such outstanding Awards; provided, however, that any fractional shares resulting from such adjustment shall be eliminated. In addition, in the event of a Change of Control, the provisions of Section 13 of the Plan shall apply. Any adjustments to outstanding Awards shall be consistent with section 409A or 424 of the Code, to the extent applicable. Notwithstanding the foregoing, for each Option or SAR with an Exercise Price or base amount, as the case may be, greater than the consideration offered in connection with any transaction or event described herein, the Committee may, in its sole discretion, elect to cancel such Option or

- 8 -


SAR without any payment to the person holding such Option or SAR. Subject to Section 18(b) below, the adjustments of Awards under this Section 4(e) shall include adjustment of shares, Exercise Price of Options, base amount of SARs, Performance Goals or other terms and conditions, as the Committee deems appropriate. The Committee shall have the sole discretion and authority to determine what appropriate adjustments shall be made and any adjustments determined by the Committee shall be final, binding and conclusive.
Section 5.    Eligibility for Participation
(a)    Eligible Persons. All Employees and Non-Employee Directors shall be eligible to participate in the Plan. Key Advisors shall be eligible to participate in the Plan if the Key Advisors render bona fide services to the Employer, the services are not in connection with the offer and sale of securities in a capital-raising transaction and the Key Advisors do not directly or indirectly promote or maintain a market for the Company’s securities.
(b)    Selection of Participants. The Committee shall select the Employees, Non-Employee Directors and Key Advisors to receive Awards and shall determine the number of shares of Company Stock subject to a particular Award in such manner as the Committee determines.
Section 6.    Options
The Committee may grant Options to an Employee, Non-Employee Director or Key Advisor upon such terms as the Committee deems appropriate. The following provisions are applicable to Options:
(a)    Number of Shares. The Committee shall determine the number of shares of Company Stock that will be subject to each Award of Options to Employees, Non-Employee Directors and Key Advisors.
(b)    Type of Option and Exercise Price.
(i)    The Committee may grant Incentive Stock Options or Nonqualified Stock Options or any combination of the two, all in accordance with the terms and conditions set forth herein. Notwithstanding such designations, to the extent that an Option designated as an Incentive Stock Option does not qualify as an Incentive Stock Option, it shall be treated as a Nonqualified Stock Option. Incentive Stock Options may be granted only to employees of the Company or its subsidiary corporations, as defined in section 424 of the Code. Nonqualified Stock Options may be granted to Employees, Non-Employee Directors and Key Advisors.
(ii)    The Exercise Price of Company Stock subject to an Option shall be determined by the Committee and shall be equal to or greater than the Fair Market Value of a share of Company Stock on the date the Option is granted. However, an Incentive Stock Option may not be granted to an Employee who, at the time of grant, owns stock possessing more than 10% of the total combined voting power of all classes of stock of the Company, or any parent or subsidiary corporation of the Company, as defined in section 424 of the Code, unless the


- 9 -


Exercise Price per share is not less than 110% of the Fair Market Value of a share of Company Stock on the date of grant.
(c)    Option Term. The Committee shall determine the term of each Option. The term of any Option shall not exceed seven years from the date of grant. However, an Incentive Stock Option that is granted to an Employee who, at the time of grant, owns stock possessing more than 10% of the total combined voting power of all classes of stock of the Company, or any parent or subsidiary corporation of the Company, as defined in section 424 of the Code, may not have a term that exceeds five years from the date of grant. Notwithstanding the foregoing, in the event that on the last business day of the term of an Option (other than an Incentive Stock Option), the exercise of the Option is prohibited by applicable law, including a prohibition on purchases or sales of Company Stock under the Company’s insider trading policy, the term of the Option shall be extended for a period of 30 days following the end of the legal prohibition, unless the Committee determines otherwise.
(d)    Exercisability of Options. Options shall become exercisable in accordance with such terms and conditions, consistent with the Plan, as may be determined by the Committee and specified in the Award Agreement. Subject to the limitations set forth in Section 13, the Committee may accelerate the exercisability of any or all outstanding Options at any time for any reason.
(e)    Awards to Nonexempt Employees. Notwithstanding the foregoing, Options granted to persons who are nonexempt employees under the Fair Labor Standards Act of 1938, as amended, may not be exercisable for at least six months after the date of grant (except that such Options may become exercisable, as determined by the Committee, upon the Participant’s death, Disability or retirement, or upon a Change of Control or other circumstances permitted by applicable regulations).
(f)    Termination of Employment or Service. Except as provided in the Award Agreement, an Option may only be exercised while the Participant is employed by, or providing services to, the Employer. The Committee shall determine in the Award Agreement under what circumstances and during what time periods a Participant may exercise an Option after termination of employment or service.
(g)    Exercise of Options. A Participant may exercise an Option that has become exercisable, in whole or in part, by delivering a notice of exercise to the Company. The Participant shall pay the Exercise Price for an Option in the method(s) specified by the Committee, which may, if permitted by the Committee, include, without limitation, one or more of the following: (i) in cash, or by check, (ii) by delivering shares of Company Stock owned by the Participant and having a Fair Market Value on the date of exercise at least equal to the Exercise Price or by attestation (on a form prescribed by the Committee) to ownership of shares of Company Stock having a Fair Market Value on the date of exercise at least equal to the Exercise Price, (iii) by payment through a broker in accordance with procedures permitted by Regulation T of the Federal Reserve Board, (iv) by withholding shares of Company Stock subject to the exercisable Option, which have a Fair Market Value on the date of exercise equal to the Exercise Price, or (v) by such other method as the Committee may approve. Shares of Company Stock used to exercise an Option shall have been held by the Participant for the

- 10 -


requisite period of time necessary to avoid adverse accounting consequences to the Company with respect to the Option. Payment for the shares to be issued or transferred pursuant to the Option, and any required withholding taxes, must be received by the Company by the time specified by the Committee depending on the type of payment being made, but in all cases prior to the issuance or transfer of such shares. Notwithstanding the foregoing, the Committee may provide, subject to any conditions it establishes in connection therewith, that if, on the last day of the Option term, the Fair Market Value of a share of Company Stock exceeds the exercise price by a specified amount, the Participant has not exercised the Option and the Option has not expired, the Option shall be deemed to have been exercised by the Participant on such day with payment made by withholding shares otherwise issuable in connection with the exercise of the Option. In such event, the Company shall deliver to the Participant the number of shares for which the Option was deemed exercised, less the number of shares required to be withheld for the payment of the total purchase price and required withholding taxes.
(h)    Limits on Incentive Stock Options. Each Incentive Stock Option shall provide that, if the aggregate Fair Market Value of the Company Stock on the date of the grant with respect to which Incentive Stock Options are exercisable for the first time by a Participant during any calendar year, under the Plan or any other stock option plan of the Company or a parent or subsidiary, exceeds $100,000, then the Option, as to the excess, shall be treated as a Nonqualified Stock Option.
Section 7.    Restricted Stock
The Committee may issue or transfer shares of Company Stock to an Employee, Non-Employee Director or Key Advisor under an award of Restricted Stock, upon such terms as the Committee deems appropriate. The following provisions are applicable to Restricted Stock:
(a)    General Requirements. Shares of Company Stock issued or transferred pursuant to Restricted Stock may be issued or transferred for consideration or for no consideration, and subject to restrictions or no restrictions, as determined by the Committee. The Committee may, but shall not be required to, establish conditions under which restrictions on Restricted Stock shall lapse over a period of time or according to such other criteria as the Committee deems appropriate, including, without limitation, restrictions based upon the achievement of specific Performance Goals. The period of time during which the Restricted Stock will remain subject to restrictions will be designated in the Award Agreement as the “Restriction Period.”
(b)    Number of Shares. The Committee shall determine the number of shares of Company Stock to be issued or transferred pursuant to an award of Restricted Stock and the restrictions applicable to such shares.
(c)    Requirement of Employment or Service. If the Participant ceases to be employed by, or provide service to, the Employer during a period designated in the Award Agreement as the Restriction Period, or if other specified conditions are not met, the Restricted Stock shall terminate as to all shares covered by the Award as to which the restrictions have not lapsed, and those shares of Company Stock must be immediately returned to the Company.

- 11 -


Subject to the limitations set forth in Section 13, the Committee may, however, provide for complete or partial exceptions to this requirement as it deems appropriate.
(d)    Restrictions on Transfer and Legend on Stock Certificate. During the Restriction Period, a Participant may not sell, assign, transfer, pledge or otherwise dispose of the shares of Restricted Stock except under Section 16 below. Unless otherwise determined by the Committee, the Company will retain possession of certificates for shares of Restricted Stock until all restrictions on such shares have lapsed. Each certificate for Restricted Stock, unless held by the Company, shall contain a legend giving appropriate notice of the restrictions in the Award. The Participant shall be entitled to have the legend removed from the stock certificate covering the shares subject to restrictions when all restrictions on such shares have lapsed. The Committee may determine that the Company will not issue certificates for Restricted Stock until all restrictions on such shares have lapsed.
(e)    Right to Vote and to Receive Dividends. Unless the Committee determines otherwise, during the Restriction Period, the Participant shall have the right to vote shares of Restricted Stock and to be credited any dividends or other distributions paid on such shares, subject to any restrictions deemed appropriate by the Committee, including, without limitation, the achievement of specific Performance Goals. Dividends shall vest and become payable only if and to the extent that the underlying Restricted Stock vests, as determined by the Committee.
(f)    Lapse of Restrictions. All restrictions imposed on Restricted Stock shall lapse upon the expiration of the applicable Restriction Period and the satisfaction of all conditions, if any, imposed by the Committee. The Committee may determine, as to any or all Restricted Stock, that the restrictions shall lapse without regard to any Restriction Period.
Section 8.    Restricted Stock Units
The Committee may grant Restricted Stock Units, each of which shall represent one hypothetical share of Company Stock, to an Employee, Non-Employee Director or Key Advisor upon such terms and conditions as the Committee deems appropriate. The following provisions are applicable to Restricted Stock Units:
(a)    Crediting of Units. Each Restricted Stock Unit shall represent the right of the Participant to receive a share of Company Stock or an amount of cash based on the value of a share of Company Stock, if and when specified conditions are met. All Restricted Stock Units shall be credited to bookkeeping accounts established on the Company’s records for purposes of the Plan.
(b)    Terms of Restricted Stock Units. The Committee may grant Restricted Stock Units that vest and are payable if specified Performance Goals or other conditions are met, or under other circumstances. Restricted Stock Units may be paid at the end of a specified performance period or other period, or payment may be deferred to a date authorized by the Committee. Subject to the limitations set forth in Section 13, the Committee may accelerate vesting or payment, as to any or all Restricted Stock Units at any time for any reason, provided such acceleration complies with section 409A of the Code, to the extent applicable. The


- 12 -


Committee shall determine the number of Restricted Stock Units to be granted and the requirements applicable to such Restricted Stock Units.
(c)    Requirement of Employment or Service. If the Participant ceases to be employed by, or provide service to, the Employer prior to the vesting of Restricted Stock Units, or if other conditions established by the Committee are not met, the Participant’s Restricted Stock Units shall be forfeited. The Committee may, however, provide for complete or partial exceptions to this requirement as it deems appropriate.
(d)    Payment With Respect to Restricted Stock Units. Payments with respect to Restricted Stock Units shall be made in cash, Company Stock or any combination of the foregoing, as the Committee shall determine.
Section 9.    Stock Appreciation Rights
The Committee may grant SARs to an Employee, Non-Employee Director or Key Advisor separately or in tandem with any Option. The following provisions are applicable to SARs:
(a)    General Requirements. The Committee may grant SARs to an Employee, Non-Employee Director or Key Advisor separately or in tandem with any Option (for all or a portion of the applicable Option). Tandem SARs may be granted either at the time the Option is granted or at any time thereafter while the Option remains outstanding; provided, however, that, in the case of an Incentive Stock Option, SARs may be granted only at the time of the grant of the Incentive Stock Option. The Committee shall establish the base amount of the SAR at the time the SAR is granted. The base amount of each SAR shall be equal to or greater than the Fair Market Value of a share of Company Stock as of the date of grant of the SAR. The term of any SAR shall not exceed seven years from the date of grant. Notwithstanding the foregoing, in the event that on the last business day of the term of a SAR, the exercise of the SAR is prohibited by applicable law, including a prohibition on purchases or sales of Company Stock under the Company’s insider trading policy, the term shall be extended for a period of 30 days following the end of the legal prohibition, unless the Committee determines otherwise.
(b)    Tandem SARs. In the case of tandem SARs, the number of SARs granted to a Participant that shall be exercisable during a specified period shall not exceed the number of shares of Company Stock that the Participant may purchase upon the exercise of the related Option during such period. Upon the exercise of an Option, the SARs relating to the Company Stock covered by such Option shall terminate. Upon the exercise of SARs, the related Option shall terminate to the extent of an equal number of shares of Company Stock.
(c)    Exercisability. A SAR shall be exercisable during the period specified by the Committee in the Award Agreement and shall be subject to such vesting and other restrictions as may be specified in the Award Agreement. Subject to the limitations set forth in Section 13, the Committee may accelerate the exercisability of any or all outstanding SARs at any time for any reason. SARs may only be exercised while the Participant is employed by, or providing service to, the Employer or during the applicable period after termination of


- 13 -


employment or service as specified by the Committee. A tandem SAR shall be exercisable only during the period when the Option to which it is related is also exercisable.
(d)    Awards to Nonexempt Employees. Notwithstanding the foregoing, SARs granted to persons who are nonexempt employees under the Fair Labor Standards Act of 1938, as amended, may not be exercisable for at least six months after the date of grant (except that such SARs may become exercisable, as determined by the Committee, upon the Participant’s death, Disability or retirement, or upon a Change of Control or other circumstances permitted by applicable regulations).
(e)    Value of SARs. When a Participant exercises SARs, the Participant shall receive in settlement of such SARs an amount equal to the value of the stock appreciation for the number of SARs exercised. The stock appreciation for a SAR is the amount by which the Fair Market Value of the underlying Company Stock on the date of exercise of the SAR exceeds the base amount of the SAR as described in subsection (a).
(f)    Form of Payment. The appreciation in a SAR shall be paid in shares of Company Stock, cash or any combination of the foregoing, as the Committee shall determine. For purposes of calculating the number of shares of Company Stock to be received, shares of Company Stock shall be valued at their Fair Market Value on the date of exercise of the SAR.
Section 10.    Other Stock-Based Awards
The Committee may grant Other Stock-Based Awards, which are awards (other than those described in Sections 6, 7, 8 and 9 of the Plan) that are based on or measured by Company Stock, to any Employee, Non-Employee Director or Key Advisor, on such terms and conditions as the Committee shall determine. Other Stock-Based Awards may be awarded subject to the achievement of Performance Goals or other criteria or other conditions and may be payable in cash, Company Stock or any combination of the foregoing, as the Committee shall determine.
Section 11.    Cash Awards
The Committee may grant Cash Awards to Employees who are executive officers and other key employees of the Company. The Committee shall determine the terms and conditions applicable to Cash Awards, including the criteria for the vesting and payment of Cash Awards. Cash Awards shall be based on such measures as the Committee deems appropriate and need not relate to the value of shares of Company Stock.
Section 12.    Dividend Equivalents
The Committee may grant Dividend Equivalents in connection with Restricted Stock Units or Other Stock-Based Awards. Dividend Equivalents may be paid currently or accrued as contingent cash obligations and may be payable in cash or shares of Company Stock, and upon such terms and conditions as the Committee shall determine. Dividend Equivalents with respect to Restricted Stock Units or Other Stock-Based Awards shall vest and be paid only if and to the extent the underlying Restricted Stock Units or Other Stock-Based Awards vest and are paid, as determined by the Committee. For the avoidance of doubt, no dividends or Dividend Equivalents will be granted in connection with Stock Options or SARs.

- 14 -


Section 13.    Consequences of a Change of Control
(a)    Assumption of Outstanding Awards. Upon a Change of Control where the Company is not the surviving corporation (or survives only as a subsidiary of another corporation), unless the Committee determines otherwise, all outstanding Awards that are not exercised or paid at the time of the Change of Control shall be assumed by, or replaced with grants that have comparable terms by, the surviving corporation (or a parent or subsidiary of the surviving corporation). After a Change of Control, references to the “Company” as they relate to employment matters shall include the successor employer in the transaction, subject to applicable law.
(b)    Vesting Upon Certain Terminations of Employment. Unless the Award Agreement provides otherwise, if a Participant’s employment is terminated by the Employer without Cause upon or within 12 months following a Change of Control, the Participant’s outstanding Awards shall become fully vested as of the date of such termination; provided that if the vesting of any such Awards is based, in whole or in part, on performance, such Awards shall vest only based on the greater of (i) actual performance as of the date of the Change of Control, or (ii) target performance, prorated based on the period elapsed between the beginning of the applicable performance period and the date of termination.
(c)    Other Alternatives. In the event of a Change of Control, if any outstanding Awards are not assumed by, or replaced with grants that have comparable terms by, the surviving corporation (or a parent or subsidiary of the surviving corporation), the Committee may take any of the following actions with respect to any or all outstanding Awards, without the consent of any Participant: (i) the Committee may determine that outstanding Stock Options and SARs shall automatically accelerate and become fully exercisable and the restrictions and conditions on outstanding Restricted Stock, Restricted Stock Units, Cash Awards, and Dividend Equivalents shall immediately lapse; (ii) the Committee may determine that Participants shall receive a payment in settlement of outstanding Restricted Stock Units, Cash Awards, or Dividend Equivalents, in such amount and form as may be determined by the Committee; (iii) the Committee may require that Participants surrender their outstanding Stock Options and SARs in exchange for a payment by the Company, in cash or Company Stock as determined by the Committee, in an amount equal to the amount, if any, by which the then Fair Market Value of the shares of Company Stock subject to the Participant’s unexercised Stock Options and SARs exceeds the Stock Option Exercise Price or SAR base amount, and (iv) after giving Participants an opportunity to exercise all of their outstanding Stock Options and SARs, the Committee may terminate any or all unexercised Stock Options and SARs at such time as the Committee deems appropriate. Such surrender, termination or payment shall take place as of the date of the Change of Control or such other date as the Committee may specify. Without limiting the foregoing, if the per share Fair Market Value of the Company Stock does not exceed the per share Stock Option Exercise Price or SAR base amount, as applicable, the Company shall not be required to make any payment to the Participant upon surrender of the Stock Option or SAR.
Section 14.    Tax Application/Changes for Certain Awards
The Committee may permit or require a Participant to defer receipt of the payment of cash or the delivery of shares that would otherwise be due to such Participant in connection with

- 15 -


any Award. If any such deferral election is permitted or required, the Committee shall establish rules and procedures for such deferrals and may provide for interest or other earnings to be paid on such deferrals. The rules and procedures for any such deferrals shall be consistent with applicable requirements of section 409A of the Code.
Section 15.    Withholding of Taxes
(a)    Required Withholding. All Awards under the Plan shall be subject to applicable United States federal (including FICA), state and local, foreign country or other tax withholding requirements. The Employer may require that the Participant or other person receiving Awards or exercising Awards pay to the Employer an amount sufficient to satisfy such tax withholding requirements with respect to such Awards, or the Employer may deduct from other wages and compensation paid by the Employer the amount of any withholding taxes due with respect to such Awards.
(b)    Share Withholding. The Committee may permit or require the Employer’s tax withholding obligation with respect to Awards paid in Company Stock to be satisfied by having shares withheld up to an amount that does not exceed the Participant’s applicable withholding tax rate for United States federal (including FICA), state and local tax liabilities. The Committee may, in its discretion, and subject to such rules as the Committee may adopt, allow Participants to elect to have such share withholding applied to all or a portion of the tax withholding obligation arising in connection with any particular Award. Unless the Committee determines otherwise, share withholding for taxes shall not exceed the Participant’s minimum applicable tax withholding amount (any determination to exceed the minimum applicable tax withholding amount shall be in accordance with permissible accounting rules then in effect).
Section 16.    Transferability of Awards
(a)    Nontransferability of Awards. Except as described in subsection (b) below, only the Participant may exercise rights under an Award during the Participant’s lifetime. A Participant may not transfer those rights except (i) by will or by the laws of descent and distribution or (ii) with respect to Awards other than Incentive Stock Options, pursuant to a domestic relations order. When a Participant dies, the personal representative or other person entitled to succeed to the rights of the Participant may exercise such rights. Any such successor must furnish proof satisfactory to the Company of his or her right to receive the Award under the Participant’s will or under the applicable laws of descent and distribution.
(b)    Transfer of Nonqualified Stock Options. Notwithstanding the foregoing, the Committee may provide, in an Award Agreement, that a Participant may transfer Nonqualified Stock Options to family members, or one or more trusts or other entities for the benefit of or owned by family members, consistent with the applicable securities laws, according to such terms as the Committee may determine; provided that the Participant receives no consideration for the transfer of an Option and the transferred Option shall continue to be subject to the same terms and conditions as were applicable to the Option immediately before the transfer.


- 16 -


Section 17.    Requirements for Issuance or Transfer of Shares
No Company Stock shall be issued or transferred in connection with any Award hereunder unless and until all legal requirements applicable to the issuance or transfer of such Company Stock have been complied with to the satisfaction of the Committee. The Committee shall have the right to condition any Award on the Participant’s undertaking in writing to comply with such restrictions on his or her subsequent disposition of the shares of Company Stock as the Committee shall deem necessary or advisable, and certificates representing such shares may be legended to reflect any such restrictions. Certificates representing shares of Company Stock issued or transferred under the Plan may be subject to such stop-transfer orders and other restrictions as the Committee deems appropriate to comply with applicable laws, regulations and interpretations, including any requirement that a legend be placed thereon.
Section 18.    Amendment and Termination of the Plan
(a)    Amendment. The Board may amend or terminate the Plan at any time; provided, however, that the Board shall not amend the Plan without stockholder approval if such approval is required in order to comply with the Code or other applicable law, or to comply with applicable stock exchange requirements.
(b)    No Repricing of Options or SARs. Except in connection with a corporate transaction involving the Company (including, without limitation, any stock dividend, distribution (whether in the form of cash, Company Stock, other securities or property), stock split, extraordinary cash dividend, recapitalization, change of control, reorganization, merger, consolidation, split-up, spin-off, combination, repurchase or exchange of shares of Company Stock or other securities, or similar transactions), the Company may not, without obtaining stockholder approval, (i) amend the terms of outstanding Stock Options or SARs to reduce the Exercise Price of such outstanding Stock Options or base price of such SARs, (ii) cancel outstanding Stock Options or SARs in exchange for Stock Options or SARs with an Exercise Price or base price, as applicable, that is less than the Exercise Price or base price of the original Stock Options or SARs or (iii) cancel outstanding Stock Options or SARs with an Exercise Price or base price, as applicable, above the current stock price in exchange for cash or other securities.
(c)    Termination of Plan. The Plan shall terminate on the day immediately preceding the tenth anniversary of its Effective Date, unless the Plan is terminated earlier by the Board or is extended by the Board with the approval of the stockholders.
(d)    Termination and Amendment of Outstanding Awards. A termination or amendment of the Plan that occurs after an Award is made shall not materially impair the rights of a Participant unless the Participant consents or unless the Committee acts under Section 19(f) below. The termination of the Plan shall not impair the power and authority of the Committee with respect to an outstanding Award. Whether or not the Plan has terminated, an outstanding Award may be terminated or amended under Section 19(f) below or may be amended by agreement of the Company and the Participant consistent with the Plan, provided that the Participant’s consent is not required if any termination or amendment to the Participant’s


- 17 -


outstanding Award does not materially impair the rights or materially increase the obligations of the Participant.
Section 19.    Miscellaneous
(a)    Awards in Connection with Corporate Transactions and Otherwise. Nothing contained in the Plan shall be construed to (i) limit the right of the Committee to make Awards under the Plan in connection with the acquisition, by purchase, lease, merger, consolidation or otherwise, of the business or assets of any corporation, firm or association, including Awards to employees thereof who become Employees, or (ii) limit the right of the Company to grant stock options or make other awards outside of the Plan. The Committee may make an Award to an employee of another corporation who becomes an Employee by reason of a corporate merger, consolidation, acquisition of stock or property, reorganization or liquidation involving the Company, in substitution for a stock option or stock award grant made by such corporation. Notwithstanding anything in the Plan to the contrary, the Committee may establish such terms and conditions of the new Awards as it deems appropriate, including setting the Exercise Price of Options or the base price of SARs at a price necessary to retain for the Participant the same economic value as the prior options or rights.
(b)    Governing Document. The Plan shall be the controlling document. No other statements, representations, explanatory materials or examples, oral or written, may amend the Plan in any manner. The Plan shall be binding upon and enforceable against the Company and its successors and assigns.
(c)    Funding of the Plan. The Plan shall be unfunded. The Company shall not be required to establish any special or separate fund or to make any other segregation of assets to assure the payment of any Awards under the Plan. To the extent a Participant acquires a right to receive payments from the Company pursuant to an Award, such right shall be no greater than the right of any general unsecured creditor of the Company.
(d)    Rights of Participants. Nothing in the Plan shall entitle any Employee, Non-Employee Director, Key Advisor or other person to any claim or right to receive an Award under the Plan. Neither the Plan nor any action taken hereunder shall be construed as giving any individual any rights to be retained by or in the employ of the Employer or any other employment rights.
(e)    No Fractional Shares. No fractional shares of Company Stock shall be issued or delivered pursuant to the Plan or any Award. Except as otherwise provided under the Plan, the Committee shall determine whether cash, other awards or other property shall be issued or paid in lieu of such fractional shares or whether such fractional shares or any rights thereto shall be forfeited or otherwise eliminated.
(f)    Compliance with Law.
(i)    The Plan, the exercise of Options and SARs and the obligations of the Company to issue or transfer shares of Company Stock under Awards shall be subject to all applicable laws and regulations, and to approvals by any governmental or regulatory agency as may be required. With respect to persons subject to section 16 of the Exchange Act, it is the

- 18 -


intent of the Company that the Plan and all transactions under the Plan comply with all applicable provisions of Rule 16b-3 or its successors under the Exchange Act. In addition, it is the intent of the Company that Incentive Stock Options comply with the applicable provisions of section 422 of the Code, and that, to the extent applicable, Awards comply with the requirements of section 409A of the Code. To the extent that any legal requirement of section 16 of the Exchange Act or section 422 or 409A of the Code as set forth in the Plan ceases to be required under section 16 of the Exchange Act or section 422 or 409A of the Code, that Plan provision shall cease to apply. The Committee may revoke any Award if it is contrary to law or modify an Award to bring it into compliance with any valid and mandatory government regulation. The Committee may also adopt rules regarding the withholding of taxes on payments to Participants. The Committee may, in its sole discretion, agree to limit its authority under this Section.
(ii)    The Plan is intended to be exempt from or, to the extent applicable, comply with, the requirements of section 409A of the Code. Any reference in this Plan to section 409A of the Code also include any regulation promulgated thereunder or any other formal guidance issued by the Internal Revenue Service with respect to section 409A of the Code. Each Award shall be construed and administered such that the Award either (A) qualifies for an exemption from the requirements of section 409A of the Code or (B) satisfies the requirements of section 409A of the Code. If an Award is subject to section 409A of the Code, (I) distributions shall only be made in a manner and upon an event permitted under section 409A of the Code, (II) payments to be made upon a termination of employment or service shall only be made upon a “separation from service” under section 409A of the Code, (III) unless the Award specifies otherwise, each installment payment shall be treated as a separate payment for purposes of section 409A of the Code, and (IV) in no event shall a Participant, directly or indirectly, designate the calendar year in which a distribution is made except in accordance with section 409A of the Code.
(iii)    Any Award that is subject to section 409A of the Code and that is to be distributed to a Key Employee (as defined below) upon separation from service shall be administered so that any distribution with respect to such Award shall be postponed for six months following the date of the Participant’s separation from service, if required by section 409A of the Code. If a distribution is delayed pursuant to section 409A of the Code, the distribution shall be paid within 15 days after the end of the six-month period. If the Participant dies during such six-month period, any postponed amounts shall be paid within 90 days of the Participant’s death. The determination of “Key Employees,” including the number and identity of persons considered Key Employees and the identification date, shall be made by the Committee or its delegate each year in accordance with section 416(i) of the Code and the “specified employee” requirements of section 409A of the Code. For the avoidance of doubt, the determination of Key Employees shall not affect the group of key employees who may be granted cash awards under Section 11 of the Plan.
(iv)    Notwithstanding anything in the Plan or any Award agreement to the contrary, each Participant shall be solely responsible for the tax consequences of Awards under the Plan, and in no event shall the Company or any subsidiary or affiliate of the Company have any responsibility or liability if an Award does not meet any applicable requirements of section 409A of the Code. Although the Company intends to administer the Plan to prevent

- 19 -


taxation under section 409A of the Code, the Company does not represent or warrant that the Plan or any Award complies with any provision of federal, state, local or other tax law.
(g)    Establishment of Subplans. The Committee shall have the discretionary authority to adopt and implement from time to time such addenda or subplans to the Plan as it may deem necessary in order to bring the Plan into compliance with applicable laws and regulations of any foreign jurisdictions in which Awards are to be made under the Plan and/or to obtain favorable tax treatment in those foreign jurisdictions for the individuals to whom the Awards are made.
(h)    Clawback Rights. Subject to the requirements of applicable law, the Committee may provide in any Award Agreement that, if a Participant breaches any non-competition, non-solicitation or other restrictive covenant agreement between the Participant and the Employer (which may be set forth or cross-referenced in any Award Agreement) or otherwise engages in activities that constitute Cause either while employed by, or providing service to, the Employer or within a specified period of time thereafter, all Awards held by the Participant shall terminate, and the Company may rescind any exercise of an Option or SAR and the vesting of any other Award and delivery of shares upon such exercise or vesting (including pursuant to dividends and Dividend Equivalents), as applicable on such terms as the Committee shall determine, including the right to require that in the event of any such rescission, (i) the Participant shall return to the Company the shares received upon the exercise of any Option or SAR and/or the vesting and payment of any other Award (including pursuant to dividends and Dividend Equivalents) or, (ii) if the Participant no longer owns the shares, the Participant shall pay to the Company the amount of any gain realized or payment received as a result of any sale or other disposition of the shares (or, in the event the Participant transfers the shares by gift or otherwise without consideration, the Fair Market Value of the shares on the date of the breach of the restrictive covenant agreement (including a Participant’s Award Agreement containing restrictive covenants) or activity constituting Cause), net of the price originally paid by the Participant for the shares. Payment by the Participant shall be made in such manner and on such terms and conditions as may be required by the Committee. The Employer shall be entitled to set off against the amount of any such payment any amounts otherwise owed to the Participant by the Employer. The Committee may also provide in any Award Agreement that if a Participant fails to timely execute or otherwise agree to be bound by a non-competition, non-solicitation or other restrictive covenant agreement with the Employer, then the Awards subject to such Award Agreement shall terminate. In addition, all Awards under the Plan shall be subject to any applicable clawback provisions or policies, recoupment provisions or policies, share trading policies and other policies that may be implemented by the Board from time to time, whether approved before or after the date of grant of an Award. In the event of a clawback, recoupment or forfeiture event under an applicable clawback policy (including without limitation a clawback policy required to be implemented by an applicable stock exchange), the amount required to be clawed back, recouped or forfeited pursuant to such policy shall be deemed not to have been earned under the terms of the Plan, and the Company shall be entitled to recover from the Participant the amount specified under the policy to be clawed back, recouped or forfeited.
(i)    Governing Law. The validity, construction, interpretation and effect of the Plan and Award Agreements issued under the Plan shall be governed and construed by and

- 20 -


determined in accordance with the laws of the Commonwealth of Massachusetts, without giving effect to the conflict of laws provisions thereof.
Approvals:
2019 Long-Term Incentive Compensation Plan
Adopted by the Board of Directors on:
May 14, 2019
2019 Long-Term Incentive Compensation Plan
Adopted by the Stockholders on:
July 25, 2019
Amended and Restated 2019 Long-Term Incentive Compensation Plan
Adopted by the Board of Directors on:
June 12, 2023
Amended and Restated 2019 Long-Term Incentive Compensation Plan
Adopted by the Stockholders on:
August 4, 2023


- 21 -
EX-99.1 3 a8kex991-pressrelease8723.htm EX-99.1 Document

Exhibit 99.1
image_0.jpg
Investor Contacts:
Olga Guyette, Sr. Director-Investor Relations & Treasury
(781) 356-9763
olga.guyette@haemonetics.com
David Trenk, Manager-Investor Relations
(203) 733-4987
david.trenk@haemonetics.com
Media Contact:
Josh Gitelson, Director-Global Communications
(781) 356-9776
josh.gitelson@haemonetics.com

Diane M. Bryant Joins Haemonetics' Board of Directors

BOSTON, Aug. 7, 2023 -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, has announced the election of Diane M. Bryant to its Board of Directors.

Bryant recently served as Chairman and Chief Executive Officer of NovaSignal Corp., a medical technology and data company specializing in the assessment and management of brain health. She is the former Chief Operating Officer of Google Cloud and spent 32 years at Intel Corporation, where she held numerous leadership roles of increasing responsibility, including serving as Group President of the Data Center Group. Bryant was named one of Fortune’s 50 Most Powerful Women in Business in 2015 and 2016. She also serves on the board of directors of Broadcom Inc. and the Chancellor’s Board of Advisors at the University of California, Davis.

Bryant received a Bachelor of Science in electrical engineering from the University of California, Davis, and she attended the Stanford Graduate School of Business, completing the Executive Program.

“Diane brings to Haemonetics’ Board more than three decades of executive leadership, directing the growth of prominent global technology organizations,” said Ellen Zane, Chair of Haemonetics’ Board of Directors. “As Haemonetics continues to extend its industry leadership, we look forward to leveraging Diane’s extensive technology and healthcare experience and strategic counsel towards achieving the company’s goals for long-term, transformational growth.”

About Haemonetics
Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing a suite of innovative medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Our technology addresses important medical markets: blood and plasma component collection, the surgical suite and hospital transfusion services. To learn more about Haemonetics, visit www.haemonetics.com.



EX-101.SCH 4 hae-20230804.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 hae-20230804_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Tax Identification Number Entity Tax Identification Number Entity Central Index Key Entity Central Index Key Entity Address, Address Line One Entity Address, Address Line One Trading Symbol Trading Symbol Entity File Number Entity File Number Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Soliciting Material Soliciting Material Entity Address, City or Town Entity Address, City or Town Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Local Phone Number Local Phone Number Entity Address, Postal Zip Code Entity Address, Postal Zip Code Written Communications Written Communications City Area Code City Area Code Cover [Abstract] Title of 12(b) Security Title of 12(b) Security Document Type Document Type Amendment Flag Amendment Flag Security Exchange Name Security Exchange Name Entity Registrant Name Entity Registrant Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Address, State or Province Entity Address, State or Province Document Period End Date Document Period End Date Pre-commencement Tender Offer Pre-commencement Tender Offer EX-101.PRE 6 hae-20230804_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 7 image_0.jpg GRAPHIC begin 644 image_0.jpg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end XML 8 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Document and Entity Information
Aug. 04, 2023
Cover [Abstract]  
Document Type 8-K
Document Period End Date Aug. 04, 2023
Entity Registrant Name HAEMONETICS CORPORATION
Entity Central Index Key 0000313143
Amendment Flag false
Entity Incorporation, State or Country Code MA
Entity File Number 001-14041
Entity Tax Identification Number 04-2882273
Entity Address, Address Line One 125 Summer Street
Entity Address, City or Town Boston
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02110
City Area Code 781
Local Phone Number 848-7100
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, $.01 par value per share
Trading Symbol HAE
Security Exchange Name NYSE
Entity Emerging Growth Company false
XML 9 hae-20230804_htm.xml IDEA: XBRL DOCUMENT 0000313143 2023-08-04 2023-08-04 0000313143 false 8-K 2023-08-04 HAEMONETICS CORPORATION MA 001-14041 04-2882273 125 Summer Street Boston MA 02110 781 848-7100 false false false false Common stock, $.01 par value per share HAE NYSE false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 1 22 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Document and Entity Information Sheet http://www.haemonetics.com/role/DocumentandEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports hae-20230804.htm a8kex101-ar2019ltiplan8723.htm a8kex991-pressrelease8723.htm hae-20230804.xsd hae-20230804_lab.xml hae-20230804_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "hae-20230804.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 22 }, "contextCount": 1, "dts": { "inline": { "local": [ "hae-20230804.htm" ] }, "labelLink": { "local": [ "hae-20230804_lab.xml" ] }, "presentationLink": { "local": [ "hae-20230804_pre.xml" ] }, "schema": { "local": [ "hae-20230804.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "hae", "nsuri": "http://www.haemonetics.com/20230804", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hae-20230804.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.haemonetics.com/role/DocumentandEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hae-20230804.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.haemonetics.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.haemonetics.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.haemonetics.com/role/DocumentandEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.haemonetics.com/role/DocumentandEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.haemonetics.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.haemonetics.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.haemonetics.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.haemonetics.com/role/DocumentandEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.haemonetics.com/role/DocumentandEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.haemonetics.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.haemonetics.com/role/DocumentandEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.haemonetics.com/role/DocumentandEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.haemonetics.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.haemonetics.com/role/DocumentandEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.haemonetics.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.haemonetics.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.haemonetics.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.haemonetics.com/role/DocumentandEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.haemonetics.com/role/DocumentandEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.haemonetics.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.haemonetics.com/role/DocumentandEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.haemonetics.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 16 0000313143-23-000037-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000313143-23-000037-xbrl.zip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